Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Headache Pain ; 25(1): 141, 2024 Aug 28.
Article in English | MEDLINE | ID: mdl-39198753

ABSTRACT

BACKGROUND: Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, but it is not clear yet to which extent this has clinical relevance. METHODS: We examined the effect of zavegepant on the relaxations induced by calcitonin gene-related peptide (CGRP) in human isolated middle meningeal arteries. Furthermore, we connected the pharmacodynamics and pharmacokinetics of gepants by combining data from clinical and basic research. RESULTS: We showed that 10 nM zavegepant potently antagonized the functional response to CGRP. We also showed that all gepants are effective at inhibiting functional responses to CGRP at their therapeutic plasma concentrations. CONCLUSIONS: The relatively low predicted potency of zavegepant to inhibit CGRP-induced relaxation at therapeutic systemic plasma concentrations may point to the relevance of local delivery to the trigeminovascular system through intranasal administration. This approach may have additional benefits for various groups of patients, including overweight patients.


Subject(s)
Administration, Intranasal , Calcitonin Gene-Related Peptide , Migraine Disorders , Humans , Migraine Disorders/drug therapy , Migraine Disorders/blood , Calcitonin Gene-Related Peptide/blood , Calcitonin Gene-Related Peptide/pharmacokinetics , Male , Meningeal Arteries/drug effects , Adult , Female , Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacokinetics , Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage , Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology , Middle Aged , Azepines/pharmacokinetics , Azepines/administration & dosage , Azepines/pharmacology
2.
Proc Natl Acad Sci U S A ; 109(46): 18985-90, 2012 Nov 13.
Article in English | MEDLINE | ID: mdl-23112192

ABSTRACT

Cortical spreading depression (CSD) is a key pathogenetic step in migraine with aura. Dysfunctions of voltage-dependent and receptor-operated channels have been implicated in the generation of CSD and in the pathophysiology of migraine. Although a known correlation exists between migraine and release of the calcitonin gene-related peptide (CGRP), the possibility that CGRP is involved in CSD has not been examined in detail. We analyzed the pharmacological mechanisms underlying CSD and investigated the possibility that endogenous CGRP contributes to this phenomenon. CSD was analyzed in rat neocortical slices by imaging of the intrinsic optical signal. CSD was measured as the percentage of the maximal surface of a cortical slice covered by the propagation of intrinsic optical signal changes during an induction episode. Reproducible CSD episodes were induced through repetitive elevations of extracellular potassium concentration. AMPA glutamate receptor antagonism did not inhibit CSD, whereas NMDA receptor antagonism did inhibit CSD. Blockade of voltage-dependent sodium channels by TTX also reduced CSD. CSD was also decreased by the antiepileptic drug topiramate, but not by carbamazepine. Interestingly, endogenous CGRP was released in the cortical tissue in a calcium-dependent manner during CSD, and three different CGRP receptor antagonists had a dose-dependent inhibitory effect on CSD, suggesting a critical role of CGRP in this phenomenon. Our findings show that both glutamate NMDA receptors and voltage-dependent sodium channels play roles in CSD. They also demonstrate that CGRP antagonism reduces CSD, supporting the possible use of drugs targeting central CGRP receptors as antimigraine agents.


Subject(s)
Calcitonin Gene-Related Peptide/pharmacokinetics , Cerebral Cortex/metabolism , Cortical Spreading Depression/drug effects , Animals , Anticonvulsants/pharmacology , Calcitonin Gene-Related Peptide/pharmacology , Calcitonin Gene-Related Peptide Receptor Antagonists , Carbamazepine/pharmacology , Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Dose-Response Relationship, Drug , Fructose/analogs & derivatives , Fructose/pharmacology , Male , Migraine Disorders/drug therapy , Migraine Disorders/metabolism , Migraine Disorders/pathology , Migraine Disorders/physiopathology , Rats , Rats, Wistar , Receptors, AMPA/antagonists & inhibitors , Receptors, AMPA/metabolism , Receptors, Calcitonin Gene-Related Peptide/metabolism , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/metabolism , Topiramate , Voltage-Gated Sodium Channels
3.
Br J Pharmacol ; 132(5): 1145-53, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11226146

ABSTRACT

Specific mechanisms, providing reuptake of cathecholamine and amino acid neurotransmitters (e.g. serotonin and glutamate) into cells of the central nervous system are well known, whereas neuronal uptake of neuropeptide transmitters have not previously been reported. In the present study we present evidence for uptake of the 37 amino acid neuropeptide, calcitonin gene-related peptide (CGRP) into perivascular terminals of capsaicin sensitive nerve fibres, innervating the guinea-pig basilar artery. Release of CGRP from perivascular nerve terminals was obtained by capsaicin-induced vanilloid receptor-stimulation and detected as CGRP receptor-mediated dilation of isolated segments of the guinea-pig basilar artery. Following three repeated capsaicin challenges, CGRP-depleted segments were incubated with CGRP. This caused significant reappearance of capsaicin-induced vasodilatory responses. These responses were dependent on duration and concentration of the preceding CGRP incubation and were inhibited by the CGRP receptor antagonist, CGRP(8 - 37). The CGRP-re-depletion was significantly reduced when CGRP(8 - 37) was present during the preceding CGRP incubation. Thus, presynaptic CGRP receptors are likely to be involved in neuronal CGRP uptake. Incubating the artery segments with (125)I-CGRP allowed subsequent detection of capsaicin-induced (125)I-release. Immunohistochemical experiments showed that only terminal CGRP is subject to capsaicin-induced depletion in vitro, whereas CGRP-immunoreactivity endures in the nerve fibres.


Subject(s)
Basilar Artery/metabolism , Calcitonin Gene-Related Peptide/pharmacokinetics , Presynaptic Terminals/metabolism , Vasodilation/physiology , Animals , Basilar Artery/drug effects , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Capsaicin/pharmacology , Guinea Pigs , Miotics/pharmacokinetics , Peptide Fragments/pharmacokinetics , Presynaptic Terminals/drug effects , Vasodilation/drug effects
4.
J Neurosci Methods ; 87(2): 195-200, 1999 Mar 01.
Article in English | MEDLINE | ID: mdl-11230816

ABSTRACT

Recently we presented a method to label the neuropeptide substance P with a 1.4-nm gold particle covalently bound at the N-terminus that can be used for demonstrating its binding sites in histological sections. In this study we examined whether the peptides neuropeptide Y, somatostatin, calcitonin gene-related peptide and bradykinin can be labelled in the same way. Polyacrylamide gel electrophoresis revealed a reduction in mobility for peptide-gold conjugates over gold particles alone consistent with peptide binding. In cryostat sections of the rat lumbar spinal cord, the peptides showed a distinct binding pattern in the grey matter corresponding to data of studies using autoradiographic methods. Therefore, we conclude that this simple and fast method can be used for labelling peptides in general to demonstrate their binding sites in histological sections, provided the peptide binds by its C-terminus.


Subject(s)
Gold Colloid/chemistry , Gold Colloid/pharmacokinetics , Neurons/chemistry , Neuropeptides/analysis , Neuropeptides/pharmacokinetics , Spinal Cord/chemistry , Animals , Binding Sites/drug effects , Binding Sites/physiology , Bradykinin/analysis , Bradykinin/pharmacokinetics , Calcitonin Gene-Related Peptide/analysis , Calcitonin Gene-Related Peptide/pharmacokinetics , Male , Neurons/cytology , Neurons/drug effects , Neuropeptide Y/analysis , Neuropeptide Y/pharmacokinetics , Posterior Horn Cells/chemistry , Posterior Horn Cells/cytology , Posterior Horn Cells/drug effects , Rats , Rats, Wistar , Somatostatin/analysis , Somatostatin/pharmacokinetics , Spinal Cord/cytology , Spinal Cord/drug effects
5.
J Physiol Pharmacol ; 55(1 Pt 2): 165-77, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15082876

ABSTRACT

Limitation of the damage to the organs such as heart, liver, intestine, stomach and brain by an earlier brief complete occlusion of their arteries is defined as ischemic preconditioning (IP). No study so for has been undertaken to check whether brain-gut axis is involved in the gastroprotection exhibited by gastric IP or in that induced by repeated brief episodes of ischemia of remote organs such as heart and liver. This study was designed to determine the possible involvement of vagal and sensory afferent nerves, in the mechanism of gastric and remote organ IP on the gastric mucosa in rats exposed to prolonged ischemia-reperfusion with or without functional ablation of sensory nerves by capsaicin or in those with removed vagal innervation by vagotomy. This gastric IP was induced by short ischemia episodes (occlusion of celiac artery 1-5 times for 5 min) applied 30 min before subsequent ischemia followed by 3 h of reperfusion (I/R) and compared with remote IP induced by occlusion of left descending coronary artery or hepatic artery plus portal vein. The area of gastric lesions was determined by planimetry, gastric blood flow (GBF) was measured by H(2)-gas clearance method and mucosal biopsy samples were taken for the assessment of calcitonin gene-related peptide (CGRP) by RIA. Exposure of gastric mucosa to standard 3 h of I/R produced numerous gastric lesions and significant fall in the GBF and mucosal CGRP content. Two 5 min short ischemic episodes by occlusion of coronary or hepatic arteries, significantly reduced gastric damage induced by I/R with the extent similar to that exhibited by two short (5 min) episodes of gastric ischemia. These protective effects of gastric and remote IPs were accompanied by a restoration of the fall in the CGRP content caused by I/R alone. Protection and hyperemia induced by gastric IP were significantly attenuated in capsaicin-denervated or vagotomized animals and completely removed in those exposed to the combination of vagotomy and capsaicin-denervation. The IP-induced protection and hyperemia were restored by the administration of exogenous CGRP to gastric IP in capsaicin-treated animals. Gastroprotective and hyperemic actions of remote IP were markedly diminished in capsaicin-denervated rats and in those subjected to vagotomy. We conclude that brief ischemia in remote organs such as heart and liver protects gastric mucosa against gastric injury induced by I/R as effectively as gastric IP via mechanism involving both vagal and sensory nerves releasing vasodilatatory mediators such as CGRP.


Subject(s)
Brain/physiology , Gastric Mucosa/blood supply , Gastric Mucosa/physiopathology , Gastrointestinal Tract/physiology , Ischemic Preconditioning/methods , Reperfusion Injury/prevention & control , Animals , Calcitonin Gene-Related Peptide/administration & dosage , Calcitonin Gene-Related Peptide/pharmacokinetics , Capsaicin/administration & dosage , Capsaicin/adverse effects , Celiac Artery/injuries , Coronary Vessels/anatomy & histology , Coronary Vessels/injuries , Heart Injuries/etiology , Heart Injuries/physiopathology , Injections, Subcutaneous , Liver/blood supply , Liver/injuries , Liver/innervation , Male , Neurons, Afferent/drug effects , Neurons, Efferent/drug effects , Peptide Fragments/administration & dosage , Peptide Fragments/pharmacokinetics , Rats , Rats, Wistar , Reperfusion Injury/etiology , Stomach Diseases/drug therapy , Stomach Diseases/physiopathology , Stomach Diseases/prevention & control , Vagotomy/methods , Vagus Nerve/drug effects , Vagus Nerve/physiopathology
6.
Arch Oral Biol ; 35(1): 63-6, 1990.
Article in English | MEDLINE | ID: mdl-2202278

ABSTRACT

The distribution of VIP- and CGRP-containing nerve fibres was examined by indirect immunofluorescence. There were many such fibres in the lower third of the ligament, some around the blood vessel close to the socket wall. In the middle third of the ligament, some CGRP-containing fibers entered from the lateral wall of the socket; this type of fibre was more numerous in the lower third than in middle third. There were some VIP-containing fibres but no CGRP-containing fibres in the ligament surrounding the furcation of the molar roots.


Subject(s)
Calcitonin Gene-Related Peptide/pharmacokinetics , Periodontal Ligament/metabolism , Vasoactive Intestinal Peptide/pharmacokinetics , Alveolar Process/blood supply , Animals , Blood Vessels/innervation , Fluorescent Antibody Technique , Male , Mice , Mice, Inbred Strains , Molar , Nerve Fibers/metabolism , Periodontal Ligament/blood supply , Periodontal Ligament/innervation
7.
J Am Soc Mass Spectrom ; 22(9): 1660-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21953269

ABSTRACT

PEGylation is a successful strategy to improve the pharmacokinetic and pharmaceutical properties of therapeutic peptides. However, quantitative analysis of PEGylated peptides in biomatrix by LC-MS/MS poses significant analytical challenge due to the polydispersity of the polyethylene glycol (PEG), and the multiple charge states observed for both the peptide and PEG moieties. In this report, a novel LC-MS/MS method for direct quantitative analysis of 20 kDa PEGylated CGRP[Cit, Cit] in cynomolgus monkey serum is presented. CGRP[Cit, Cit] is an investigational human calcitonin gene peptide receptor antagonist with amino acid sequence Ac -WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPT DVGPFAF-NH(2). In-source collision-induced dissociation (in-source CID) of 20 kDa PEGylated peptide was used to generate CGRP[Cit, Cit] fragment ions, among which the most abundant b(8)(+) ion was selected and measured as a surrogate for the 20 kDa PEGylated peptide. A solid phase extraction (SPE) method was used to extract the PEGylated peptides from the biomatrix prior to the UPLC-MS/MS analysis. This method achieved a lower limit of quantitation (LLOQ) of 5.00 ng/mL with a serum sample volume of 100 µL, and was linear over the calibration range of 5.00 to 500 ng/mL in cynomolgus monkey serum. Intraday and interday accuracy and precision from QC samples were within ±15%. This method was successfully applied to a pharmacokinetic study of the 20 kDa PEGylated CGRP[Cit, Cit] in cynomolgus monkeys.


Subject(s)
Calcitonin Gene-Related Peptide Receptor Antagonists , Calcitonin Gene-Related Peptide/blood , Chromatography, High Pressure Liquid/methods , Polyethylene Glycols/analysis , Tandem Mass Spectrometry/methods , Amino Acid Sequence , Animals , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide/chemistry , Calcitonin Gene-Related Peptide/pharmacokinetics , Humans , Least-Squares Analysis , Macaca fascicularis , Molecular Sequence Data , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Reproducibility of Results
9.
Aust N Z J Surg ; 64(4): 266-9, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8147781

ABSTRACT

Calcitonin gene-related peptide (CGRP) is a 37 amino-acid peptide, undetectable in the plasma in health but elevated in certain disease states such as medullary thyroid cancer, and potentially causes symptoms. The kidney is a major site of and influence on the clearance of exogenously infused CGRP. As CGRP might cause symptoms in renal dysfunction, this study was performed to determine the clearance of CGRP in humans and animals with altered renal function. In chronic renal failure patients, CGRP was not detected in plasma either before or after haemodialysis. In sheep, before and after bilateral nephrectomy, there was an approximate halving of plasma clearance and doubling of the circulating half-life of infused CGRP. This reduction in clearance was greater than that which could be accounted for by the reduction in degradation by renal substance alone. This renal influence on extra-renal CGRP metabolism was not due to the renal production of a circulating peptidase as evidenced by the absence of such peptidase in the plasma of normal and anephric sheep. Further, severity of uraemia had no influence on the extra-renal metabolism. The mechanism by which the kidney influences the extra-renal metabolism of CGRP remains obscure.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Kidney Failure, Chronic/metabolism , Kidney/metabolism , Animals , Calcitonin Gene-Related Peptide/blood , Calcitonin Gene-Related Peptide/pharmacokinetics , Half-Life , Humans , Metabolic Clearance Rate , Nephrectomy , Renal Dialysis , Sheep
10.
Z Orthop Ihre Grenzgeb ; 128(3): 240-2, 1990.
Article in German | MEDLINE | ID: mdl-2168110

ABSTRACT

Calcitonin is the most important hypocalcaemic peptide. Its action is brought about through inhibition of bone resorption. CGRP exerts the same effect on the skeleton albeit in much higher concentrations probably through interaction with calcitonin receptors on osteoclasts. PAS-57 stimulates the incorporation of thymidine into osteoblasts. A possible stimulation of bone formation needs to be verified in vivo.


Subject(s)
Calcitonin Gene-Related Peptide/pharmacology , Calcitonin/pharmacology , Peptide Fragments/pharmacology , Bone Resorption/prevention & control , Calcitonin Gene-Related Peptide/pharmacokinetics , Humans , Osteoblasts/metabolism , Osteoclasts/drug effects , Osteogenesis/drug effects , Receptors, Calcitonin , Receptors, Cell Surface/metabolism , Thymidine/metabolism
11.
J Cardiovasc Pharmacol ; 42(4): 511-20, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14508237

ABSTRACT

The vasorelaxant effects of N-[4-O-[2-methoxy, phenoxyethylaminobutyl]-3-methoxy benzyl]-nonamide (VOA), a novel capsaicin derivative, and associated releasing activities of nitric oxide (NO) and calcitonin gene-related peptide (CGRP) were investigated in this study. Systemic administration of VOA decreased blood pressure and heart rate in a dose-dependent manner in both normotensive as well as spontaneously hypertensive rats. Nw-nitro-L-arginine methyl ester (L-NAME), glibenclamide, and capsazepine inhibited VOA-induced hypotension. In phenylephrine-precontracted rat aortic rings and mesenteric arteries with intact endothelium, VOA caused a concentration-dependent relaxation. This relaxation was reduced after endothelium was removed or pretreated with L-NAME, methylene blue, 1 H-[1,2,4]oxidazolol [4,3-a] quinoxalin-1-one, tetraethylammonium, glibenclamide, CGRP (8-37), or capsazepine, respectively. In endothelially denuded vessel rings, tetraethylammonium, glibenclamide, CGRP (8-37), and capsazepine also reduced VOA-induced relaxation. In high potassium (80 mmol/L)-precontracted rat aortic rings with intact endothelium, VOA failed to induce relaxation. VOA induced a concentration-dependent increase of CGRP-like enzyme immunoreactivity, which was also significantly inhibited by capsazepine. In human umbilical vein endothelial cells, VOA increased NO release and guanosine-3', 5'-cyclic monophosphate level, which were significantly inhibited by L-NAME. The Western blot analysis on human umbilical vein endothelial cells indicated that VOA increased the expression of endothelium nitric oxide synthase. In conclusion, VOA might exert its relaxation effects in rat vascular smooth muscle through the CGRP/KATP channel and the NO/ cGMP pathway.


Subject(s)
Aorta, Thoracic/drug effects , Capsaicin/pharmacokinetics , Mesenteric Arteries/drug effects , Vasodilation/drug effects , Vasodilator Agents/pharmacokinetics , Animals , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide/pharmacokinetics , Capsaicin/administration & dosage , Capsaicin/analogs & derivatives , Cells, Cultured , Cyclic GMP/metabolism , Dose-Response Relationship, Drug , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Humans , Hypertension/drug therapy , Hypertension/genetics , Muscle, Smooth, Vascular/drug effects , Nitric Oxide/physiology , Nitric Oxide Synthase/metabolism , Potassium Channels/physiology , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Umbilical Arteries/drug effects , Umbilical Arteries/metabolism , Vasodilator Agents/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL